PRECISION BIOSCIENCES INC - 8-K Filing

Precision BioSciences announces successful Phase 1 ELIMINATE-B clinical trial results for PBGENE-HBV and advances program to Phase 2. (Items: 7.01 Regulation FD DisclosureOn November 5, 2026, Precision BioSciences, Inc, 8.01 Other EventsOn November 5, 2026, the Company issued the HBV News Release announcing a late-breaking oral presentation at the American Associa, 9.01 Financial Statements and Exhibits)

SEC EDGAR · November 5, 2026, 12:01 UTC

Tickers: $DTIL

Read the full article at SEC EDGAR

More Regulatory news

SAGA COMMUNICATIONS INC - 8-K Filing SEC EDGAR · November 12, 2026, 14:05 UTC
NextBoat Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 14:05 UTC
CIVISTA BANCSHARES, INC. - 8-K Filing SEC EDGAR · November 12, 2026, 14:05 UTC
RF Acquisition Corp II - 10-Q Filing SEC EDGAR · November 12, 2026, 14:04 UTC
ORASURE TECHNOLOGIES INC - 10-Q Filing SEC EDGAR · November 12, 2026, 14:03 UTC
Rocket Companies, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 14:03 UTC
Applied Aerospace & Defense, Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 14:02 UTC
Palomar Holdings, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 14:02 UTC
UNITED GUARDIAN INC - 10-Q Filing SEC EDGAR · November 12, 2026, 14:00 UTC
Dare Bioscience, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 14:00 UTC